SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:liu-202318"
 

Search: onr:"swepub:oai:DiVA.org:liu-202318" > Ixazomib, Lenalidom...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Partanen, AnuKuopio Univ Hosp, Finland (author)

Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group

  • Article/chapterEnglish2024

Publisher, publication year, extent ...

  • MDPI,2024
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-202318
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-202318URI
  • https://doi.org/10.3390/cancers16051024DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:238473382URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:155240493URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Funding Agencies|BMS
  • Scarce data exist on double maintenance in transplant-eligible high-risk (HR) newly diagnosed multiple myeloma (NDMM) patients. This prospective phase 2 study enrolled 120 transplant-eligible NDMM patients. The treatment consisted of four cycles of ixazomib-lenalidomide-dexamethasone (IRD) induction plus autologous stem cell transplantation followed by IRD consolidation and cytogenetic risk-based maintenance therapy with lenalidomide + ixazomib (IR) for HR patients and lenalidomide (R) alone for NHR patients. The main endpoint of the study was undetectable minimal residual disease (MRD) with sensitivity of <10-5 by flow cytometry at any time, and other endpoints were progression-free survival (PFS) and overall survival (OS). We present the preplanned analysis after the last patient has been two years on maintenance. At any time during protocol treatment, 28% (34/120) had MRD < 10-5 at least once. At two years on maintenance, 66% of the patients in the HR group and 76% in the NHR group were progression-free (p = 0.395) and 36% (43/120) were CR or better, of which 42% (18/43) had undetectable flow MRD <10-5. Altogether 95% of the patients with sustained MRD <10-5, 82% of the patients who turned MRD-positive, and 61% of those with positive MRD had no disease progression at two years on maintenance (p < 0.001). To conclude, prolonged maintenance with all-oral ixazomib plus lenalidomide might improve PFS in HR patients.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Waage, AndersSt Olavs Hosp, Norway (author)
  • Peceliunas, ValdasVilnius Univ Hosp, Lithuania (author)
  • Schjesvold, FredrikOslo Univ Hosp, Norway; Univ Oslo, Norway (author)
  • Anttila, PekkaUniv Helsinki, Finland (author)
  • Saeily, MarjaanaOulu Univ Hosp Hematol, Finland (author)
  • Uttervall, KatarinaKarolinska Institutet,Karolinska Univ Hosp, Sweden; Karolinska Inst, Sweden (author)
  • Putkonen, MerviTurku Univ Hosp, Finland (author)
  • Carlson, KristinaUppsala Univ Hosp, Sweden (author)
  • Haukas, EinarStavanger Univ Hosp, Norway (author)
  • Sankelo, MarjaTampere Univ Hosp Hematol, Finland (author)
  • Szatkowski, DamianFoerde Cent Hosp, Norway (author)
  • Hansson, MarkusSkane Univ Hosp, Sweden (author)
  • Marttila, AnuKymenlaakso Cent Hosp, Finland (author)
  • Svensson, RonaldRegion Östergötland, Hematologiska kliniken US(Swepub:liu)ronsv17 (author)
  • Axelsson, PerHelsingborg Hosp, Sweden (author)
  • Lauri, BirgittaSunderby Hosp, Sweden (author)
  • Mikkola, MaijaPaijat Hame Cent Hosp, Finland (author)
  • Karlsson, ConnyHalland Hosp, Sweden (author)
  • Abelsson, JohannaUddevalla Cent Hosp, Sweden (author)
  • Ahlstrand, ErikOrebro Univ Hosp, Sweden (author)
  • Sikioe, AnuCent Finland Cent Hosp, Finland (author)
  • Klimkowska, MonikaKarolinska Univ Hosp, Sweden (author)
  • Matuzeviciene, RedaVilnius Univ Hosp, Lithuania; Vilnius Univ, Lithuania (author)
  • Fenstad, Mona HoysaeterSt Olavs Hosp, Norway (author)
  • Ilveskero, SorellaUniv Helsinki, Finland (author)
  • Pelliniemi, Tarja-TerttuFimlab Labs Ltd, Finland (author)
  • Nahi, HarethKarolinska Univ Hosp Huddinge, Sweden (author)
  • Silvennoinen, RaijaUniv Helsinki, Finland (author)
  • Kuopio Univ Hosp, FinlandSt Olavs Hosp, Norway (creator_code:org_t)

Related titles

  • In:Cancers: MDPI16:52072-6694

Internet link

Find in a library

  • Cancers (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view